Pelthos Therapeutics Inc. — fact timeline

Pelthos Therapeutics Inc. engaged Grant Thornton LLP as its auditor.

“Also on May 16, 2026, the Audit Committee approved the engagement of Grant Thornton LLP (“Grant Thornton”), as its new independent registered public accounting firm.”

Pelthos Therapeutics Inc. dismissed CBIZ CPAs P.C. as its auditor.

“On May 16, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Pelthos Therapeutics Inc. (the “Company”) approved the dismissal of CBIZ CPAs P.C. (“CBIZ”), as the Company’s independent registered public accounting firm.”

Francis Knuettel II was terminated as Chief Financial Officer, Treasurer and Secretary at Pelthos Therapeutics Inc..

“the Board terminated Francis Knuettel II from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective April 10, 2026.”

Pelthos Therapeutics Inc. entered into Venture Loan and Security Agreement with Horizon Technology Finance Corporation valued at aggregate principal amount of up to $50.0 million (effective 2026-01-12).

“On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).”

Pelthos Therapeutics Inc. entered into Asset Purchase Agreement with Hatchtech Pty Ltd valued at $1,800,000 aggregate purchase price (including $450,000 down payment paid on November 20, 2025 and $ (effective 2025-12-23).

“On December 23, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”) entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Hatchtech Pty Ltd ACN 098 559 409, an Australian corporation (“ Hatchtech ”), pursuant to which Hatchtech sold all of its right, title and interest in (i) the product developed by Hatchtech with Abametapir as its sole active ingredient for the treatment of head lice infestation in humans (the “ Xeglyze Product ”), (ii) all intangible assets of Hatchtech including intellectual property of Hatchtech relating to the Xeglyze Product, including, without limitation (A) certain patent and patent applications, together with all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, and renewals and (B) certain trademarks, service marks, trade names and registered user names, including registrations and applications for registration thereof, together with all goodwill associated therewi”

Pelthos Therapeutics Inc. incurred convertible notes of $18.0 million with Investors, including Ligand Pharmaceuticals Incorporated at 8.5% per annum (increases to 18.0% in the event of default) maturing November 6, 2027.

“On November 6, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain investors, including Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Ligand ”) (collectively, the “ Investors ”), pursuant to which, among other things, on the Closing Date, the Investors purchased for cash, and the Company issued and sold to the Investors, senior secured convertible notes of the Company (the “ Convertible Notes ”) in the aggregate original principal amount of $18.0 million, which are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) (such transaction, the “ Convertible Note Financing ”).”

Pelthos Therapeutics Inc. completed an acquisition involving LNHC, Inc. and Ligand Pharmaceuticals Incorporated (closed 2025-07-01).

“On July 1, 2025, Channel Therapeutics Corporation, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand consummated the Merger”

Pelthos Therapeutics Inc.: Company effected a reverse stock split at a 1:10 ratio effective July 1, 2025 (effective 2025-07-01).

“the Company effected the Reverse Stock Split pursuant to the Reverse Stock Split Certificate of Amendment.”

Pelthos Therapeutics Inc.: Company changed name from Channel Therapeutics Corporation to Pelthos Therapeutics, Inc.

“the Company changed its name from “Channel Therapeutics Corporation” to “Pelthos Therapeutics, Inc.” pursuant to the Name Change Certificate of Amendment.”